Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Nov 24

PMID 29168755

Citations 90

Authors

Matthias Schmidt

Alexander Rohe

Charlott Platzer

Abdulkarim Najjar

Frank Erdmann

Wolfgang Sippl

Affiliations

Soon will be listed here.

Abstract

In the cell cycle, there are two checkpoint arrests that allow cells to repair damaged DNA in order to maintain genomic integrity. Many cancer cells have defective G1 checkpoint mechanisms, thus depending on the G2 checkpoint far more than normal cells. G2 checkpoint abrogation is therefore a promising concept to preferably damage cancerous cells over normal cells. The main factor influencing the decision to enter mitosis is a complex composed of Cdk1 and cyclin B. Cdk1/CycB is regulated by various feedback mechanisms, in particular inhibitory phosphorylations at Thr14 and Tyr15 of Cdk1. In fact, Cdk1/CycB activity is restricted by the balance between WEE family kinases and Cdc25 phosphatases. The WEE kinase family consists of three proteins: WEE1, PKMYT1, and the less important WEE1B. WEE1 exclusively mediates phosphorylation at Tyr15, whereas PKMYT1 is dual-specific for Tyr15 as well as Thr14. Inhibition by a small molecule inhibitor is therefore proposed to be a promising option since WEE kinases bind Cdk1, altering equilibria and thus affecting G2/M transition.

Citing Articles

N-Glycoside of Indolo[2,3-]pyrrolo[3,4-]carbazole LCS1269 Exerts Anti-Glioblastoma Effects by G2 Cell Cycle Arrest and CDK1 Activity Modulation: Molecular Docking Studies, Biological Investigations, and ADMET Prediction.

Kalitin N, Koroleva N, Lushnikova A, Babaeva M, Samoylenkova N, Savchenko E Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770484 PMC: 11676706. DOI: 10.3390/ph17121642.

Knockdown of ribosomal protein L22-like 1 arrests the cell cycle and promotes apoptosis in colorectal cancer.

Li C, Du X, Zhang H, Liu S Cytojournal. 2024; 21:45.

PMID: 39737125 PMC: 11683392. DOI: 10.25259/Cytojournal_29_2024.

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression.

Baird J, Alice A, Saito R, Chai Q, Han M, Ng C Sci Rep. 2024; 14(1):29913.

PMID: 39622844 PMC: 11612208. DOI: 10.1038/s41598-024-80677-8.

Discovery of novel and highly potent dual-targeting PKMYT1/HDAC2 inhibitors for hepatocellular carcinoma through structure-based virtual screening and biological evaluation.

Yang Y, Wang Y, Chen J, Niu M, Wang Y, Jin X Front Pharmacol. 2024; 15:1491497.

PMID: 39619613 PMC: 11604427. DOI: 10.3389/fphar.2024.1491497.

Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.

Li M, Lulla A, Wang Y, Tsavaschidis S, Wang F, Karakas C Cancer Res. 2024; 84(22):3864-3880.

PMID: 39186665 PMC: 11567801. DOI: 10.1158/0008-5472.CAN-23-4130.

References

Wolanin P, Thomason P, Stock J . Histidine protein kinases: key signal transducers outside the animal kingdom. Genome Biol. 2002; 3(10):REVIEWS3013. PMC: 244915. DOI: 10.1186/gb-2002-3-10-reviews3013. View

Dixon H, Norbury C . Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle. 2003; 1(6):362-8. DOI: 10.4161/cc.1.6.257. View

Johnson L, Noble M, Owen D . Active and inactive protein kinases: structural basis for regulation. Cell. 1996; 85(2):149-58. DOI: 10.1016/s0092-8674(00)81092-2. View

Rohe A, Gollner C, Wichapong K, Erdmann F, Al-Mazaideh G, Sippl W . Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay. Eur J Med Chem. 2012; 61:41-8. DOI: 10.1016/j.ejmech.2012.06.007. View

Caldwell J, Edwards H, Buck S, Ge Y, Taub J . Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer. 2014; 61(10):1767-73. PMC: 4199830. DOI: 10.1002/pbc.25081. View

Gavet O, Pines J . Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. J Cell Biol. 2010; 189(2):247-59. PMC: 2856909. DOI: 10.1083/jcb.200909144. View

Lindqvist A, van Zon W, Rosenthal C, Wolthuis R . Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol. 2007; 5(5):e123. PMC: 1858714. DOI: 10.1371/journal.pbio.0050123. View

McGowan C, Russell P . Cell cycle regulation of human WEE1. EMBO J. 1995; 14(10):2166-75. PMC: 398322. DOI: 10.1002/j.1460-2075.1995.tb07210.x. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

10.

Larochelle S, Merrick K, Terret M, Wohlbold L, Barboza N, Zhang C . Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell. 2007; 25(6):839-50. PMC: 1858677. DOI: 10.1016/j.molcel.2007.02.003. View

11.

Kawabe T . G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 2004; 3(4):513-9. View

12.

Zuccotto F, Ardini E, Casale E, Angiolini M . Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem. 2009; 53(7):2681-94. DOI: 10.1021/jm901443h. View

13.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

14.

Mueller P, Leise 3rd W . Measurement of Wee kinase activity. Methods Mol Biol. 2004; 296:299-328. DOI: 10.1385/1-59259-857-9:299. View

15.

Chow J, Poon R . The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene. 2012; 32(40):4778-88. DOI: 10.1038/onc.2012.504. View

16.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

17.

Rodriguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O, Agell N . Different S/M checkpoint responses of tumor and non tumor cell lines to DNA replication inhibition. Cancer Res. 2007; 67(24):11648-56. DOI: 10.1158/0008-5472.CAN-07-3100. View

18.

Wong K, Cheng R, Mok S . Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001; 30(3):670-5. DOI: 10.2144/01303dd05. View

19.

Panek R, Lu G, KLUTCHKO S, Batley B, Dahring T, Hamby J . In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 1998; 283(3):1433-44. View

20.

Tse A, Sheikh T, Alan H, Chou T, Schwartz G . 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol. 2008; 75(1):124-33. PMC: 2685054. DOI: 10.1124/mol.108.050807. View